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Abstract
Background: The prognosis for carcinoma of the ampulla of Vater (CAV) is better than for pancreatic cancer. The 5-year
survival median rate after resection of CAV is 45%, but late recurrences remain possible. Several survival factors have been
identified (lymph nodes, perineural invasion), but few data are available on the type of recurrences, their impact and their
management. Patients and methods: A total of 41 patients treated by pancreatoduodenectomy (PD) for CAV from 1980 to 2003
were studied retrospectively. Patient selection, long-term survival recurrence rate and recurrence treatment were reviewed.
Univariate and multivariate proportional hazards analysis were conducted on this series. Results: The mean follow-up was 48
months. Five-year survival was 62.8%. Eleven patients had recurrences (667 months). Recurrence was associated with time
to all-causes death (hazard ratio [HR] 4.3, p/0.003). Factors predictive of recurrence were perineural invasion (HR 5.3,
p/0.02), lymph node invasion (HR 5.3, p/0.02) and differentiation (HR 0.2, p/0.05). Three patients underwent surgical
R0 treatment of their recurrences. Two who presented with solitary liver metastasis are alive and disease-free. Conclusions:
Recurrence represents a serious threat in the prognosis of CAV after surgery. Some of these recurrences, in particular liver
metastases, are accessible for a curative treatment. This finding supports the usefulness of a close and long-term follow-up
after surgery to improve survival of patients with CAV, especially in the group of patients with a good prognosis.
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Introduction
Carcinoma of the ampulla of Vater (CAV) is an
uncommon tumor, which accounts for 7% of peri-
pancreatic lesions [1]. Its prognosis is known to be
better than pancreatic cancer after resection. Indeed,
the 5-year survival median rate after resection has
been reported to be around 45% (from 30 to /60%)
in different series from the literature [231].
Some poor prognosis factors have been found, i.e.
the large size of the tumor, lymph node metastases,
vascular ingrowths and perineural microscopic inva-
sion [35,12,20,23,24,2831].
Recurrences have been poorly studied. Late recur-
rences have been reported but the median delay, the
type and their curability are unknown. The aim of this
study was to analyse the prognostic factors for survival
and recurrence and to study specifically the recur-
rences and their management.
Patients and methods
Patients
From January 1985 to October 2003, all consecutive
patients treated by pancreatoduodenectomy (PD) for
CAV in the Department of Surgery of Caen were
reviewed and analysed. There were 41 patients, 18
(44%) women and 23 (56%) men, with a mean age of
65 years (range 5072). Symptoms at the time of
diagnosis were jaundice (63%), right upper quadrant
pain (34%), pancreatitis and angiocholitis. One pa-
tient presented with upper gastrointestinal bleeding;
upper gastrointestinal endoscopy revealed a CAV
(Table I).
Preoperative biopsies were available in 19 cases, 13
of which were positive for adenocarcinoma (68%).
Ampullectomy had been performed previously for
three patients. Two patients were diagnosed with
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adenoma 4 and 8 years before, respectively, and one
with adenocarcinoma.
PD with lymphadenectomy was performed on all
patients with the diagnosis or suspected diagnosis of
CAV; 78% of patients had a pancreato-gastric anasto-
mosis.
A single pathologist reviewed all specimens and
patients’ records were examined for characteristics
of the initial tumor (Table I). The median size of the
tumor was 2.3 cm. The tumors were well differen-
tiated in 27 cases (65.8%). There was a mean of
11.6 nodes examined (140), with a median of
B/1 positive node (04). Four patients were treated
postoperatively with radiation therapy associated with
chemotherapy (40 Gy/5FU). Two tumors were well
differentiated. Among those, there were two T2
lesions, one T3 and one T4. All of them had lymph
node metastasis.
Methods
All patients were followed up every 3 months after
surgery with regular monitoring of recurrence by
ultrasonography or CT scan. The median follow-up
was 48 months after the PD (range 2161 months).
Clinical and histological factors of survival and
recurrence were analysed. The emphasis of the
analysis was on the population of patients who had
recurrences. We studied in detail the type of recur-
rence, the time between the initial surgery and the
recurrence, and the treatment of this recurrence.
Statistical analysis
Survival following the day of surgery was evaluated by
constructing KaplanMeier event curves in which all-
cause death was considered as failure. Univariate
analyses of factors potentially associated with survival
and recurrences (age, sex, T stage, size of the lesion,
perineural invasion, lymph node metastases, vascular
involvement, differentiation) were based on the two-
sided log-rank test. After checking the proportionality
assumption and covariate colinearity, multivariate
analysis of the time to death and time to recurrence
were performed with the Cox proportional hazards
model to assess the independent effect of these
variables. All analyses were conducted using SAS
(version 8.2, SAS Institute Inc., Cary, NC, USA).
p values B/0.05 were considered to denote statistically
significant differences. All tests were two-tailed.
Results
The 30 days postoperative and in-hospital mortality
were 0% and 2%, respectively. Eighteen patients
(43%) died during follow-up. The overall 1-year,
3-year and 5-year survival rates were 90.2%, 74.2%
and 62.8%, respectively, with a 10-year survival rate
of 34.6% (Figure 1).
On univariate analysis, age over 70, the existence of
vascular ingrowths, perineural invasion and positive
lymph nodes were statistically associated with survival
(pB/0.05). (Figure 1). In our study, neither the size of
the lesion (/2 cm) nor the differentiation of the tumor
appeared to have a significant impact on survival.
Four independent factors (age /70 years, lymph
node invasion, perineural infiltration and recurren-
ce) had a significant impact on survival (pB/0.05)
(Figure 2).
Recurrence occurred in 11 cases (26.8%), with a
median time of 24.5 months after PD (range 667
months). Recurrence occurred as follows: seven
patients experienced peritoneal metastases with in
one case liver involvement, two patients had solitary
liver metastasis, one had bilateral hepatic metastasis
and one patient had a biliary recurrence.
On multivariate analysis, three independent factors
were predictive of recurrence: lymph node metasta-
sis (HR 5.3, p/0.02), perineural invasion (HR
5.3, p/0.02) and tumor differentiation (HR 0.2,
p/0.05).
Seven patients with peritoneal metastases had
recurrences 24.8 months after initial surgery. There
were two T1 lesions, two T2 lesions, two T3 lesions
and one T4. Six of the seven patients had well
differentiated tumors. All had positive lymph nodes
on final pathology; 71% had perineural invasion,
whereas only 43% had vascular ingrowths. Three of
Table I. Baseline characteristics of patients (n/41).
Parameter Value
Male, n (%) 18 (44%)
Age (SD) 65 (5072)
T1 10 (24%)
T2 16 (39%)
T3 8 (20%)
T4 2 (5%)
Unknown 5
Differentiation
Well differentiated 27 (66%)
Unknown 6 (15%)
Lymph node involvement 13 (32%)
Vascular invasion, n (%) 16 (39%)
Perineural invasion, n (%) 8 (19.5%)
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Figure 1. Overall survival.
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these seven patients had a postoperative treatment
based on radiation and chemotherapy. These patients
were N/ and experienced peritoneal metastases 6, 18
and 26 months after the PD. Two patients were
treated for recurrence with radiation therapy and
chemotherapy, one of whom had already had a
postoperative treatment.
Two patients had isolated liver metastasis. There
were two T2 lesions with no positive lymph nodes or
vascular ingrowth. One of them had perineural inva-
sion. None of these patients had received postopera-
tive treatment. Liver metastasis was diagnosed during
systematic follow-up, at 10 and 11 months after
surgery. These lesions were both treated aggressively,
with R0 minor liver resection. Both of these two
patients are alive and tumor-free 39 and 45 months
after treatment of recurrence. One patient experi-
enced a biliary recurrence 67 months after surgical
resection of a T1 CAV. He was treated by segmen-
tectomy 4 with biliary reconstruction on a Roux-en-Y
jejunal loop. Then 33 months later he experienced an
angiocholitis, with an abscess on the right lobe of the
liver for which he was re-operated (right hepatect-
omy). On final pathology, recurrences on liver, jejunal
loop, portal vein and retroportal lymph nodes were
observed. He died 2 months after surgery. The only
patient who recurred with bilobar liver metastases was
treated by intra-arterial hepatic chemo-embolization,
at the beginning of our experience. He died early after
his first treatment.
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Figure 2. Kaplan Meier survival curves according to different baseline factors.
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Table II. Factors predictive of survival: review of the literature.
Prognosis factors
Authors (Ref. no.) Year(s) n (CAV) Periampullary tumors included Mortality rate 5-year survival N T R0 VI PNI Diff Others
Seller & Machachek [2] 1993 18 Y 40%
Shutze et al. [3] 19531988 24 N 12.50% 61% /
Chan et al. [4] 19601991 29 Y 42% (disease-free) / / Chemotherapy
Monson et al. [5] 19651989 104 N 6% 34% / / / /
Su et al. [6] 19651995 132 N 15.20% 37.50% / / / /75 years, ht /30%, urea
B/20 mg/dl
Talamini et al. [7] 19691996 106 N 4% 38.00% / / Perioperative transfusion
Yeo et al. [8] 19701992 46 Y 39%
Chareton et al. [9] 19701992 63 N 40%
Dorandeu et al. [10] 19701992 45 N 44% / /
Sperti et al. [11] 19711990 36 N 3% 56% / / /
Klempnaueur et al. [12] 19711995 85 N 9.60% 38.20% / / /
Sielezneff et al. [13] 19711995 39 N 10% 35% / / /
Kayahara et al. [14] 19741994 36 N 8% 56%
Shirai et al. [15] 19751991 56 N 2.50% 45% /
Allema et al. [16] 19751993 982 12% 35%
Menon et al. [17] 19751997 13 N 0% 38% /
Andersen et al. [18] 19761991 25 Y 34% /
Willett et al. [19] 19811990 29 N 55%
Beger et al. [20] 19821997 126 Y 52% if R0 / / /
Matory et al. [21] 19831990 69 N 43% Resectability
Howe et al. [22] 19831995 101 N 5% 44% / /
Tanaka et al. [23] 19831999 16 N 0% 50.50% / / /
Allema et al. [24] 19841992 62 N 6% 50% /
Bottger et al. [25] 19851994 31 N 63% /
Stephens et al. [26] 19851995 28 Y 41% /
Kingsnorth [27] 19871995 29 Y 34%
Lee et al. [28] 19881997 39 N 5% 55% (3-year survival) /
Duffy et al. [29] 19882001 55 N 0 67.70% /
de Castro et al. [30] 19922002 145 N 5% 37% / / /
Brown et al. [31] 19912004 51 N 2% 58% /
Hansel et al. [32] N / / / CDX
N, lymph node metastases; T, tumor stage; R0, curative resection; VI, vascular invasion; PNI, perineural invasion; Diff, tumor differentiation; CDX, caudal type homeodomain transcription factors.
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Discussion
Our study confirms the good results of curative
resection for CAV, possible in all cases in our series,
with a low postoperative mortality rate. Series in the
literature vary 13 to more than 100 patients, reviewed
on at least 10 year. Our serie is monocentric, reviewing
41 patients operated on a 18 year period of time.
The 5-year survival rates reported in different series
in the literature vary from 35% to 67.7% [232]
(Table II). In the first period of time, from 1975 until
1993, the 5-year survival rate reported among 932
patients was 35% [16]. An increase of this survival
was observed during the following 20 years, with a 5-
year survival rate of nearly 45% (3467.7%). With a
5-year survival rate of 62.8%, we report one of the
four top survival rates of /60% [25,29] (Table II).
Many different prognosis factors have been re-
ported in the literature. The most common one is
lymph node metastasis. Indeed many series report a
better survival when no lymph node metastasis was
found [3,4,8,13,17,30]. The other most common
factors found in literature were resection margin
status [24], tumor differentiation [6,13,15], T stage
[5,6,12,13,16] and perineural invasion [23,29,30].
The existence of vascular invasion was observed less
frequently [5,23] (Table II).
Our study points out the same prognosis factors but
multivariate analysis emphasizes the impact of peri-
neural invasion on all-cause mortality. Among pa-
tients who experienced a curable recurrence, all were
N, but two-thirds had perineural invasion. If we
focus on modalities of tumor relapse, several char-
acteristics can be outlined, as described below.
First, recurrence after PD for CAV is a frequent
event, occurring in about 50% of patients [23,28,33].
Recurrence is linked to the tumor characteristics and
especially to the T and N stages. Indeed, de Castro et
al. reported an increased rate of recurrence varying
from 32% in T1T3N0 stages and 100% for T4N/
lesions [33]. Tumor differentiation is also predictive of
recurrence [5,6,12,13]. An interesting aspect of our
patients who had recurrences was that they had
predictive factors of favorable outcomes on pathology
(i.e. no lymph node metastasis).
Second, the site of first recurrence appears to be
mainly in the liver, the tumor bed and the peritoneum
[11,33]. Lung and bilateral ovarian metastases were
among other sites reported [11,34]. In contrast, we
report the first case of metastatic biliary ingrowths,
appearing 67 months after resection, probably be-
cause of biliary dysplasia associated with the ampul-
loma. But our experience suggests a low rate of
solitary liver metastasis (5%).
Third, the delay of recurrence is an important fact
concerning the need for a long follow-up. Indeed,
after PD, patients are usually followed for 5 years with
systematic ultrasound examination. Most recurrences
occur in the first 3 years [23,31], with 25% in the first
6 months after surgery according to de Castro et al.
[33]. But late recurrences have also been reported
(42114 months) [11,33]. In our series we found only
26.8% of patients who had recurrences with a mean
time to recurrence of 27.6 months. The latest
recurrence occurred 67 months after PD.
Consequently, even if this tumor seems to have a
good prognosis in terms of survival, a close and long-
term follow-up in CAV should be recommended, to
detect treatable recurrences at an early stage.
As regards the curative treatment of these recur-
rences, very few data are available in current litera-
ture. Liver metastases are the most frequently
curatively treated. Fujii et al. in 1999 reported two
liver resections for CAV metastasis [35]. Both patients
were diagnosed with unilobar liver metastases 22 and
23 months after PD. They were operated on (ex-
tended left hepatectomy and right hepatectomy) but
experienced an early recurrence. In 2002 Yoshida
et al. reported one case of liver metastasis 19 months
after PD for a T2N1 CAV [36]. This 51-year-old
woman was treated with preoperative and postopera-
tive chemotherapy and was still alive with no sign of
recurrence 18 months after surgery. In our series, we
report two patients (5%) who recurred with unique
liver tumors, 10 months after PD. They were operated
on and are still alive with no sign of recurrence 45 and
39 months after liver surgery.
The treatment of such liver recurrences definitely
leads to an increase in survival, in contrast with a
short survival of 4.7 months after the diagnosis of
metastasis [33]. Local bed recurrences are often
associated with peritoneal metastases, and no curative
treatment is available.
In our series, we experienced one biliary tumor
budding 67 months after PD, which was successfully
treated with liver and bile duct resection, allowing a
long-term survival.
To conclude, our experience shows that treatment of
recurrence is possible in some selected cases, espe-
cially for solitary liver metastasis and seems to allow a
long-lasting survival. We suggest a careful and long-
term follow-up even in patients with good prognosis
factors. As these recurrences are mostly asymptomatic,
systematic monitoring by ultrasonography or CT scan
is advisable, especially in the first 3 years. An aggres-
sive treatment of such recurrences is also advisable.
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